INHERITED INFERTILITY - MAPPING LOCI ASSOCIATED WITH IMPAIRED FEMALE REPRODUCTION

Sanni Ruotsalainen¹, Juha Karjalainen^{1,2,3,4,5}, Mitja Kurki^{1,2,3,4,5}, Elisa Lahtela¹, Matti Pirinen^{1,6,7}, Juha Riikonen¹, Jarmo Ritari⁸, Silja Tammi⁸, Jukka Partanen⁸, Hannele Laivuori^{1,9,10,11}, FinnGen^{*}, Aarno Palotie^{1,2,3,4,5,12}, Henrike Heyne^{1,2,13,14,15}, Mark Daly^{1,2,3,4,5}, Elisabeth Widen^{1**}

- 1) Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
- 2) Program for Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 3) Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- 4) Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
- 5) Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
- 6) Department of Mathematics and Statistics, University of Helsinki, Helsinki, Finland
- 7) Department of Public Health, University of Helsinki, Helsinki, Finland
- 8) Finnish Red Cross Blood Service, R&D, Helsinki, Finland
- 9) Medical and Clinical Genetics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
- 10) Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland
- 11) Faculty of Medicine and Health Technology, Center for Child, Adolescent and Maternal Health Research, University of Tampere, Tampere, Finland
- 12) Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
- 13) Digital Health Center, Hasso Plattner Institute for Digital Engineering, University of Potsdam, Potsdam, Germany
- 14) Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- * A full list of the FinnGen research team members appears at the end of the paper.

**Corresponding author

E-mail: elisabeth.widen@helsinki.fi

ABSTRACT

Female infertility is a common and complex health problem affecting millions of women worldwide. While multiple factors can contribute to this condition, the underlying cause remains elusive in up to 15-30% of cases. In our large genomewide association study (GWAS) of 22,849 women with infertility and 198,989 controls from the Finnish population cohort FinnGen, we unveil a unique landscape of genetic factors associated with the disease. Our recessive analysis identified a lowfrequency stop-gained mutation in TBPL2 (p.Arg331Ter; minor allele frequency (MAF) = 1.2%) with an impact comparable to highly penetrant monogenic mutations $(OR = 650, p = 4.1 \times 10^{-25})$. While previous studies have linked the homologous gene to anovulation and sterility in knockout mice, the severe consequence of the p.Arg331Ter mutation was evidenced by homozygous carriers having significantly fewer offspring (average of 0.16) compared to women belonging to the other genotype groups (average of 1.75 offspring, $p = 1.4 \times 10^{-15}$). Notably, all homozygous women who had given birth had received infertility therapy. Moreover, our agestratified analyses identified three additional genome-wide significant loci. Two loci were associated with early-onset disease (infertility diagnosed before age 30), located near CHEK2 and within the major histocompatibility complex (MHC) -region. The third locus, associated with late-onset disease, had its lead SNP located in an intron of a IncRNA gene. Taken together, our data highlight the significance of rare recessive alleles in shaping female infertility risk. The results further provide evidence supporting specific age-dependent mechanisms underlying this complex disorder.

1 INTRODUCTION

Infertility affects millions of individuals of reproductive age worldwide. WHO estimates that the lifetime prevalence of infertility in the Americas and Europe is 20% and 16.5%, respectively.¹ Although infertility may stem from factors related both to women and men, it is commonly attributed to female factors, either entirely or in part.² Ovarian dysfunction is a prevalent underlying reason, and age-related infertility is also on the rise due to delayed childbirth. Yet in 15-30% of cases, the cause of infertility remains unexplained despite thorough clinical investigation.^{2,3}

9

10 Certain pre-existing conditions, such as polycystic ovarian syndrome (PCOS), 11 endometriosis, and uterine fibroids, are associated with increased infertility risk in 12 women. Genome-wide association studies (GWAS) have identified 20, 40, and 30 13 common variant loci linked to these conditions, respectively, implicating hormone signaling and cell growth pathways.⁴⁻⁶ A more recent GWAS meta-analysis of 14 15 40,024 women affected by infertility from 6 different cohorts further identified 16 significant genetic correlations between all-cause female infertility and endometriosis 17 and fibroids, and a correlation between anovulatory infertility and polycystic ovary syndrome (PCOS)⁷. In that study, the majority of the 19 reported infertility loci were 18 19 also associated with endometriosis, PCOS, or fibroids.⁷

20

While the previous GWAS analyses of infertility and its related disorders in women have targeted common genetic variation, it can be expected that rare or lowfrequency recessive variants may be particularly significant causes of impaired reproduction. In fact, our previous exploration of over 40,000 coding variants across >2,000 disease phenotypes in the Finnish population cohort FinnGen, revealed a

26	recessive association of female infertility with low-frequency variant near
27	PKHDL1/EBAG9.8 That study comprised 7,980 women affected by infertility. We now
28	present results from an expanded recessive association analysis encompassing
29	22,849 women affected by infertility and 198,989 controls from the FinnGen cohort.
30	Genetic drift and historical bottlenecks have shaped the Finnish population structure
31	leading to an enrichment of genetic variants in the 0.5-5% allele frequency range in
32	the current population. ⁹ Thus, we expect the FinnGen cohort to be highly potent and
33	well-suited for the successful identification of such mutations impacting reproduction.

34 SUBJECTS AND METHODS

35 Study cohort and data

36 We studied female infertility in the large Finnish research project FinnGen[®] 37 (https://www.finngen.fi/en) launched in 2017. FinnGen is a public-private research 38 project, combining genome and digital healthcare data on over 500,000 Finns. The 39 nationwide research project aims to provide novel medically and therapeutically 40 relevant insight into human diseases. FinnGen is a pre-competitive partnership of 41 Finnish biobanks and their background organizations (universities and university 42 hospitals) and international pharmaceutical industry partners and Finnish biobank 43 All cooperative (FINBB). FinnGen partners are listed here: 44 https://www.finngen.fi/en/partners. This study is based on FinnGen data release 12 45 including 520,210 participants of which 293,373 (56,39 %) are females.

46

47 Definition of female infertility

48 The clinical disease endpoint 'female infertility' was constructed based on the 49 register codes using the Finnish version of the International Classification of 50 Diseases, 10th revision (ICD-10) diagnosis codes and harmonizing them with 51 definitions from ICD-8 and ICD-9 as follow: at least one record of female infertility 52 diagnosis (N97* or N98* [ICD-10], or 628* [ICD8 and 9]), or at least one record of 53 purchased medication used for infertility treatments (ATC codes G03GA* or 54 G03GB*) or a record of a procedure used for treatment of infertility (e.g. 55 insemination), (NOMESCO codes: TLW00, TLW10, TLW11, TLW12, TLW14 or 56 TLW20). Women with an infertility record including only ICD10 code N97.4 ("Female 57 infertility associated with male factors") were excluded from the analyses. As

- 58 controls, we used women who have given birth based on data from the Medical Birth
- 59 Register and the Finnish Population Register. Using these criteria, we
- 60 identified 22,849 women affected by infertility and 198,989 controls.
- 61
- 62 **Table 1:** Basic characteristics of the study cohort.

	All	Cases	Controls
N (%)	221,838 [100]	22,849 [10.29]	198,989 [89.70]
Age (mean [SD]) ^a	61.40 [16.33]	51.09 [12.91]	62.59 [16.26]
BMI (mean [SD]) ^b	27.50 [5.72]	27.21 [5.96]	27.53 [5.69]
Given birth (N [%])	216,469 [97.57]	17,480 [76.50]	198,989 [100]
Age at first birth (mean [SD]) $^{\circ}$	26.20 [5.11]	30.22 [5.77]	25.84 [4.89]
N offspring (mean [SD])	2.22 [1.22]	1.50 [1.19]	2.30 [1.19]
Endometriosis (N [%])	16,618 [7.49]	4,607 [20.16]	12,011 [6.03]
PCOS (N [%])	1,691 [0.76]	1,011 [4.42]	590 [0.29]
Leiomyoma of uterus (N [%])	35 199 [15.86]	3 346 [14.64]	31 853 [16.01]

63

^a Age at end of follow-up or death

^b BMI information available only for 150,636 [67.90 %] women (15,453 [67.63 %] cases and 135 183
[67.93 %] controls

^c Information available only for women who have given birth at least once (n = 216,469, 17,489 cases
and 198,989 controls).

69

The basic clinical characteristics of cases and controls are presented in **Table 1**. Given that the Drug Reimbursement Register contains data starting from 1995, women who have received in vitro fertilization (IVF) therapy prior to this date cannot be identified as cases unless they have received a record of infertility in the Hospital Discharge Register (HILMO). In addition, given that our resolution to distinguish

between cases and controls is much higher for women suffering from reduced fertility starting from the mid-1990's, the FinnGen women identified as cases are younger than the controls (difference of the mean = 11.99 years, $p < 1 \times 10^{-324}$; **Supplementary Figure 1**). In the analyses, this age difference has been considered by using birth year as a covariate in the GWAS analyses, and when calculating the disease prevalence. In the analyses of disease enrichment, both cases and controls have been matched by birth year.

82

5,701 (24.95 %) of cases were secondary infertility cases, i.e., they received the infertility diagnosis after having at least one child. On average, the cases with infertility who have at least one child were on average 4.37 years older than controls when giving birth for the first time ($p < 1 \times 10^{-324}$; **Supplementary Figure 2**)

87

88 Genotyping and imputation

89 FinnGen samples were genotyped with multiple Illumina and Affymetrix arrays 90 (Thermo Fisher Scientific, Santa Clara, CA, USA). Genotype calls were made with 91 GenCall and zCall algorithms for Illumina and AxiomGT1 algorithm for Affymetrix 92 chip genotyping data batch-wise. Genotyping data produced with previous chip 93 platforms were lifted over to build version 38 (GRCh38/hg38) following the protocol 94 described here: dx.doi.org/10.17504/protocols.io.ngtddwn. Samples with sex 95 discrepancies, high genotype missingness (>2%), excess heterozygosity in 96 common variants (allele frequency > 0.05) (±3SD) per batch, and non-Finnish 97 ancestry were removed. Variants with high missingness (>2%), deviation from Hardy–Weinberg equilibrium ($P \square < \square 1 \times 10^{-6}$) and low minor allele count (MAC $\square < \square 3$) 98 99 were removed.

100

101 Pre-phasing of genotyped data was performed with Eagle 2.3.5 102 (https://data.broadinstitute.org/alkesgroup/Eagle/) with the default parameters, 103 except the number of conditioning haplotypes was set to 20,000. Imputation of the 104 genotypes was carried out by using the population-specific Sequencing Initiative 105 Suomi (SISu) v4.2 imputation reference panel with Beagle 4.1 (version 08Jun17.d8b, 106 https://faculty.washington.edu/browning/beagle/b4_1.html) as described in the 107 following protocol: dx.doi.org/10.17504/protocols.io.nmndc5e. SISu v4.2 imputation 108 reference panel was developed using the high-coverage (25-30x) whole-genome 109 sequencing data generated at the Broad Institute of MIT and Harvard and at the 110 McDonnell Genome Institute at Washington University, USA; and jointly processed 111 at the Broad Institute. Variant callset was produced with Genomic Analysis Toolkit 112 (GATK) HaplotypeCaller algorithm by following GATK best practices for variant 113 calling. Genotype-, sample- and variant-wise quality control was applied in an 114 iterative manner by using the Hail framework v0.2. The resulting high-quality WGS 115 data for 3,775 individuals were phased with Eagle 2.3.5 as described above. As a 116 post-imputation quality control, variants with INFO score < 0.7 were excluded.

117

118 Genome-wide association study

119 A total of 221,838 (22,849 cases and 198,989 controls) female samples from 120 FinnGen Data Freeze 12 were analyzed using REGENIE¹⁰. All models were adjusted 121 for age at the end of follow-up or death, birth year, genotyping batch, and first ten 122 principal components (PC). Both additive and recessive models were performed, 123 using imputed genotypes (n variants = 21,296,962). Recessive analyses were 124 performed for variants with at least 2 homozygous carriers for the minor allele (n

variants = 15,421,131). All variants reaching genome-wide significance p-value threshold of 5×10^{-8} were considered genome-wide significant (GWS). All GWS regions were fine-mapped using SUSIE¹¹, and independent genome-wide significant loci were determined as 'good quality' credible sets from those analyses.

To investigate the effect of advanced maternal age on reduced fertility, we also performed age-stratified GWAS. Based on the maternal age corresponding to the first record of female infertility, we divided our cases into 'early-onset' ('infertility diagnosis before age of 30', n = 9,185) and 'late-onset' ('infertility diagnosis after age of 30', n = 13,664) cases (**Supplementary Figure 3**). The age-stratified analyses were performed using both the additive and the recessive GWAS models, similarly as for the 'all cases' scenario described above, using the same set of controls.

136

137 Genetic correlations and disease enrichment

138 To explore the connection of female infertility with underlying disorders of female 139 reproductive traits, we calculated both 1) genetic correlations and 2) case 140 enrichments with our female infertility endpoints across 4 disease endpoints created 141 and analyzed in FinnGen: 'Endometriosis', 'Endometriosis ESRM stage 3 or 4', 142 'Leiomyoma of uterus' and 'PCOS'. A complete list of endpoints analysed in 143 definitions FinnGen, and their is available at 144 https://www.finngen.fi/en/researchers/clinical-endpoints. We also calculated 145 heritability estimates for both female infertility endpoints, as well as for all the four 146 underlying disorders of female reproductive traits listed above. Summary statistics 147 from the additive GWAS for female infertility endpoints were used to calculate 148 genetic correlations. The genetic correlations and heritability estimates were calculated using the LDSC software.^{12,13} 149

150

The prevalence in our female infertility cases and controls separately was calculated for the four underlying disorders of female reproductive traits, and its enrichment to cases vs. controls was calculated. P- values for the enrichments were calculated using Fisher's exact test¹⁴. In these analyses, controls were matched with cases for their birth year, since the birth year distribution of the controls and cases were significantly different.

157 RESULTS

158 GWAS results

159 To elucidate the genetic predisposition to female infertility, we performed GWAS 160 analyses on 22,849 women affected by from infertility and 198,989 women who had 161 given birth without a history of infertility or infertility treatment. Both a recessive and a 162 traditional additive model were used for the analyses. The recessive GWAS 163 pinpointed two genome-wide significant loci: one nearby PKHD1L1, and another at 164 TBPL2. The TBPL2 locus has not been previously associated with female infertility 165 or any disorder associated with infertility in GWAS. In contrast, PKHD1L1 has 166 previously been implicated in two GWAS analyses of female infertility- we have 167 reported a recessive association between *PKHD1L1* and female infertility⁸, while 168 Venkatesh and coworkers later reported a genome-wide significant association 169 between the locus and female infertility using an additive model⁷.

170

171 We next ran the additive GWAS analysis in our cohort of cases and controls and 172 identified genome-wide significant association at four distinct loci on chromosomes 173 1, 4, 6, and 8 near genes WNT4, SULT1B1, ESR1, and PKHD1L1, respectively. 174 Statistical fine-mapping further identified a fifth independent significant association 175 signal on ESR1 locus (Figure 1). All these loci have previously been associated 176 either with female infertility or with pre-existing conditions that increase the risk of 177 female infertility, such as endometriosis, uterine fibroids, and PCOS (Table 2). 178 Locuszoom plots for all significant GWS regions from both scans are available in 179 Supplementary Figure 4 (loci identified by the additive model) and Supplementary 180 Figure 5 (loci identified by the recessive model).




Figure 1: Manhattan plots for female infertility. Additive results are grey and recessive are
blue dots. Genome-wide significant loci (± 500 kB) have been highlighted with green and
labeled with the nearest gene of the lead variant.

185

186 Given that the *PKHD1L1* locus yielded genome-wide significant association in both 187 the recessive and the additive analyses, we analyzed the mode of inheritance for all 188 identified association signals in more detail. For this purpose, we selected the lead 189 variant (i.e. variant with the smallest p-value) at all significant loci, and plotted the 190 proportion of affected cases in each genotype group (Supplementary Figure 6 and 191 **Supplementary Figure 7**). This data confirms that both the *PKHD1L1* and *TBPL2* 192 loci exhibit a recessive mode of action, i.e. the proportion of cases with infertility is 193 significantly elevated only among homozygous carriers of the effect allele. In 194 contrast, at the remaining loci, the percentage of affected cases increases across the 195 three genotype groups consistent with an additive mode of action.

- 197 Table 2: Independent GWAS hits and their representative variants identified by either
- 198 additive or recessive model. The lead variant from the recessive and the additive models at
- the shared locus (*PKHD1L1*) are within the same credible set (LD = 1).

SNPID (rsid)	Most severe consequence	Nearest gene	OR [95% CI]	P-value	Maf	Fin enrichment ^a	Known associations ^c
			Recessive				
chr8_109459837_G_C (rs17368310) ^b	splice donor variant	PKHD1L1	2.34 [1.98-2.78]	1.47×10 ⁻²²	0.07	1.42	Female infertility
chr14_55424219_T_A (rs144313315)	stop gained	TBPL2	650.1 [190.7-2216.1]	4.11×10 ⁻²⁵	0.01	43.04	-
			Additive				
chr1_22139327_T_C (rs61768001)	intron variant	WNT4	1.10 [1.07-1.13]	4.4×10 ⁻¹²	0.16	0.99	Endometriosis, fibroids
chr4_69718365_T_G (rs13138435)	downstream gene variant	SULT1B1	0.93 0.91-0.95]	4.57×10 ⁻¹⁰	0.31	0.8	Uterine leiomyomata and fibroids
chr6_151230382_G_T (rs35977392)	upstream gene variant	ESR1	0.93 0.91-0.95]	3.97×10 ⁻¹¹	0.35	0.88	Endometriosis
chr8_109459837_G_C (rs17368310)	splice donor variant	PKHD1L1	1.19 [1.14-1.23]	3.79×10 ⁻¹⁸	0.07	1.42	Female infertility

200

201 ^a Compared to Non-Finnish Europeas in gnomAD v3¹⁵

^b Representative variant was changed to coding variant from lead variant chr8_109515401_CAAT_C

203 (rs58870933), $r^2 = 1$.

204 ^C Known associations for genes have been defined from NHGRI-EBI GWAS Catalog¹⁶ and previous

205 publications for female infertility and underlying disorders.

206

207 All three loci identified to have an additive effect showed evidence for pleiotropy, i.e.

208 assessment of the infertility-associated loci by PheWas of 2,460 endpoints in

209 FinnGen indicated association with two or more other diseases of the female

210 reproductive tract. In contrast, the two recessive loci (near *TBPL2* and *PKHD1L1*)
211 were specifically associated only with infertility (**Table 2**).

212

213 TBPL2 locus


The strongest association was observed in the recessive analysis at the *TBPL2* locus, with an OR of 650.1 ($p = 4.11 \times 10^{-25}$). The lead variant in this locus, rs144313315 (chr14:55424219_T/A), is a rare stop-gained mutation (p.Arg331Ter, MAF 1.1% in Finland) which is highly enriched to Finland (43 times compared to non-Finnish Europeans). The variant appears rather evenly distributed across Finland, with an allele frequency range of 0.84-2.38 % (**Supplementary Figure 8**).

220

221 Although infertility is a condition causing considerable stress to patients, most 222 affected women will successfully conceive a child. To assess the prognosis for 223 women carrying two copies of the TPBL2 mutation, we analyzed the number of 224 offspring in the entire FinnGen cohort across the TBPL2 genotype groups. The 225 average number of offspring among all FinnGen women with and without a history of 226 infertility is 1.50 [SD = 1.19] vs. 1.77 [SD = 1.43], respectively. However, the average 227 number of offspring was significantly reduced among homozygous female carriers of 228 the p.Arg331Ter mutation. PheWAS analysis revealed a genome-wide significant 229 recessive association between the mutation and the number of offspring ($\beta = -1.28$ 230 SD, $p = 4.25 \times 10^{-15}$) with homozygous carriers having an average of only 0.16 231 [SD=0.58] offspring. According to the registry data, only four homozygous women for 232 the TBPL2 mutation had given birth, and none of them had conceived without 233 infertility treatment (Figure 2; Supplementary Table 1). No such effect was

234 observed at the PKHD1L1 locus, where the number of offspring was only slightly

235 reduced among homozygous carriers of the minor allele (Supplementary Figure 9).



237

238 Figure 2: Average number of offspring for genotype groups for rs14413315 (TBPL2 stop-239 gained variant) separately for females and males who have reached age 45. The dashed 240 line represents the overall average number of offspring in FinnGen among women who have 241 reached age 45 (=1.96).

242

243 These data indicate that the p.Arg331Ter mutation in TPBL2 is associated with a 244 rather severe form of infertility. These results are supported by previously published 245 studies in mice, which reported that female mice lacking this gene are infertile female 246 mice due to anovulation.

248 Age-stratified analysis

249 Female fertility gradually decreases with age, starting to decline more rapidly in 250 women in their early thirties. To assess whether genetic susceptibility varies with 251 age, we conducted age-stratified analyses. We analyzed women diagnosed with or 252 treated for infertility below the age of 30 (early-onset) separately from those 253 diagnosed or treated at age 30 or above (late-onset). These age-stratified analyses 254 identified three additional genome-wide significant loci associated with infertility: two 255 with early-onset disease near CHEK2 and the major histocompatibility complex 256 (MHC) region on chromosome 9, and one with late-onset disease, with the lead SNP 257 located in an intron of the IncRNA gene ENSG00000284418 (Supplementary 258 Figure 10)

259

The strongest association signal exclusively associated with early-onset infertility was a frameshift mutation, c.1100delC (rs555607708), in *CHEK2*, which previously has been shown to confer increased risk for breast and ovarian cancer. The mutation is additionally associated with leiomyoma, thyroid cancer, and myeloproliferative disorders in FinnGen. A recent study including women from FinnGen and the Estonian biobank further reported that the mutation is associated with an increased risk for PCOS (OR = 13.46 [5.68–31.89], p = 1.68×10⁻⁹)¹⁷

267

The other association signal exclusively associated with early-onset infertility was within the major histocompatibility complex (MHC) region. To pinpoint the exact location of the signal, we imputed the classical HLA alleles as well as *MICA* and $MICB^{18}$ and tested these alleles for association with our female infertility endpoints. None of the tested variants showed significant association for any of the infertility

endpoint tested. The complete association results of these additional association
tests across the MHC region are presented in **Supplementary Table 2**.

275

276 Genetic correlations and case enrichments among cases

277 Given that three of the significantly associated loci detected by the primary GWAS 278 analyses showed pleiotropic association with female reproductive system disorders, 279 such as PCOS, endometriosis, and leiomyoma of the uterus, we next examined their 280 genetic overlap with infertility on a genomic scale. The strongest genetic correlation 281 (rg) was observed between infertility and endometriosis (rg = 0.46, p = 2.69×10^{-15}), 282 with similar correlation estimates with endometriosis found among both early-onset 283 and late-onset cases (Supplementary Figure 11). In contrast, although there was a 284 significant enrichment of PCOS among women affected by infertility (Table 3), the 285 genetic correlation between the two diseases was only 0.22 (p = 0.014). 286 Interestingly, both the genetic correlation and case enrichment with PCOS increased 287 among early-onset cases. Heritability estimates for all analyzed female infertility-288 related endpoints are presented in **Supplementary Figure 12**.

- **Table 3:** Genetic correlations with female infertility (rg) and enrichment of female infertility
- 290 cases (Enrichment) among four underlying disorders for female reproduction.

Phenotype	N cases	rg [95% Cl]	P-value (rg)	Enrichment	P-value (Enr)
Endometriosis	20 190	0.46 [0.35-0.58]	2.69×10 ⁻¹⁵	3.83	< 1× 10 ⁻³²⁴
Endometriosis ASRM stages 3,4	10 127	0.48 [0.35-0.61]	1.76×10 ⁻¹³	5.53	< 1× 10 ⁻³²⁴
Leiomyoma of uterus	42 107	0.30 [0.19-0.41]	8.78×10 ⁻⁰⁸	1.44	1.01×10 ⁻⁷³
Polycystic ovarian syndrome (PCOS)	2 214	0.22 [0.04-0.39]	0.014	9.27	< 1× 10 ⁻³²⁴

292 DISCUSSION

293 Our GWAS analyses, encompassing more than 20,000 Finnish women affected by 294 infertility and 198,000 controls, showcase a diverse landscape of associated loci. 295 The analyses reveal that a portion of unexplained female infertility may be attributed 296 to high-impact recessively acting disruptive mutations present at >1% frequency in 297 the population. Specifically, our analyses point to a mutation in the Tata-box binding 298 protein-like 2 gene (TBPL2), which encodes a transcription factor protein crucial for 299 transcription initiation during oocyte growth. Based on our findings, this mutation is a significant contributor to female infertility in Finland.¹⁹ The mutation introduces a 300 301 premature stop codon (p.Arg331Ter) in the terminal DNA-binding part of the protein, 302 and can hence be expected to significantly impair the transcription of the 303 downstream targets. In our follow-up analyses, the TBPL2 mutation was associated 304 only with infertility and no other diseases. The variant's association with a smaller 305 number of offspring suggests that the mutation is associated with severe infertility 306 Prior data have indeed shown that the absence of TBPL2 leads to oocytes failing to 307 develop and renders female mice sterile.²⁰

308

309 According to data from GnomAD (v3.1.2), loss-of-function mutations in TBPL2 are 310 rare, with the stop-gained mutation associated with infertility in this study being an 311 exception. Apart from our findings, there are only scattered reports of coding 312 mutations in TBPL2 detected in women with infertility. Three reports describe 313 homozygous and compound heterozygous stop-gained mutations (c.788+3A>G, 314 p.Arg233Ter and c.802C>T, p.Arg268Ter) in women with infertility from four unrelated Chinese families.^{21,22} In a fourth report, a homozygous missense mutation 315 316 was linked to infertility, oocyte maturation arrest, and degradation in two sisters from

a consanguineous family.²³ Notably, all published cases have exhibited treatmentresistant primary infertility. In our study, most homozygous mutation carriers had not given birth. However, based on data from the Medical Birth Register, two out of 41 carriers had given birth to one child, whereas two carriers had given birth to more than one child. All four women had undergone IVF therapy, although more detailed information on the potential use of donor oocytes is not available.

323

324 Over the past few decades, there has been a considerable shift in childbearing 325 demographics in developed countries, characterized by more women choosing to 326 delay childbearing.^{24,25} Since a woman's age is one of the key factors influencing 327 fertility, this trend has resulted in a higher average age at which women first 328 experience infertility. This pattern is also evident in FinnGen, where we observe 329 steadily increasing ages at first birth among women born between the 1950s and the 330 1980s (**Supplementary Figure 13**). Interestingly, previous research indicates 331 that the causes of infertility may differ between older and younger women, with those 332 over 35 years of age being nearly twice as likely to experience unexplained infertility 333 compared to younger women.²⁶

334

In support of specific age-dependent mechanisms, our GWAS analyses suggest that some associated loci indeed exert their effect in an age-dependent manner. Some loci, such as *TBPL2*, are uniformly associated with infertility in both early and lateonset cases, but we identified two loci uniquely associated with infertility only among women diagnosed before age 30, and one locus associated with late-onset disease. One of the loci associated with early-onset infertility is a frameshift alteration (c.1100delC) in the tumor suppressor gene *CHEK2*, associated with a 32% lifetime

risk for breast cancer.²⁷ Finding association with early-onset infertility likely reflects a link with PCOS, as the c.1100delC mutation is significantly associated with PCOS in FinnGen ¹⁶, and the proportion of PCOS cases is increased among women with early-onset infertility compared to all infertility cases (0.077 vs. 0.046, respectively).

346

347 The second locus associated with the early-onset infertility was the major 348 histocompatibility complex (MHC) region on chromosome 6. The data indicate that 349 the association is rather sharply defined to a region between 30018523 and 350 33018523 bp on chromosome 6, and fine-mapping analyses suggest that the signal 351 is not associated with the classical MHC effect. The classical MHC genes encode 352 proteins involved in antigen presentation to T cells, whereas a key function for non-353 classical MHC I molecules is to mediate inhibitory or activating stimuli in natural killer 354 (NK) cells. Given that the survival of the embryo in the uterus depends on the 355 maintenance of immune tolerance at the maternal-fetal interface, and that the 356 pregnant uterus is predominantly populated with NK cells, one may speculate that 357 the association findings tag an underlying mechanism that might be related to local 358 immune tolerance.²⁸ Further functional studies are nonetheless warranted to explore 359 and verify such an effect.

360

Taken together, our data point towards a unique landscape of genetic factors associated with female infertility. The results specifically highlight the significant role of recessive low-frequency variants, with the stop-gained mutation in *TBPL2* exhibiting an impact comparable to highly penetrant monogenic mutations.

REFERENCES

- Organization, W. H. & others. Infertility Prevalence Estimates: 1990–2021.
 2023.
- Carson, S. A. & Kallen, A. N. Diagnosis and Management of Infertility: A Review. JAMA - Journal of the American Medical Association vol. 326 Preprint at https://doi.org/10.1001/jama.2021.4788 (2021).
- 3. Sadeghi, M. R. Unexplained infertility, the controversial matter in management of infertile couples. *Journal of Reproduction and Infertility* vol. 16 Preprint at (2015).
- Day, F. *et al.* Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. *PLoS Genet* 14, (2018).
- 5. Rahmioglu, N. *et al.* The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. *Nat Genet* **55**, (2023).
- Gallagher, C. S. *et al.* Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis. *Nat Commun* **10**, (2019).
- Venkatesh, S. S. *et al.* Genome-wide analyses identify 21 infertility loci and over 400 reproductive hormone loci across the allele frequency spectrum. *medRxiv* 2023–2024 (2024).
- Heyne, H. O. *et al.* Mono- and biallelic variant effects on disease at biobank scale. *Nature* 613, (2023).
- 9. Kurki, M. I. *et al.* Author Correction: FinnGen provides genetic insights from a well-phenotyped isolated population (Nature, (2023), 613, 7944, (508-518),

 10.1038/s41586-022-05473-8).
 Nature
 Preprint
 at

 https://doi.org/10.1038/s41586-023-05837-8 (2023).

 <t

- 10. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* **53**, (2021).
- Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable selection in regression, with application to genetic fine mapping. *J R Stat Soc Series B Stat Methodol* 82, (2020).
- 12. Bulik-Sullivan, B. *et al.* LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, (2015).
- 13. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases and traits. *Nat Genet* **47**, (2015).
- 14. Fisher, R. A. On the Interpretation of χ 2 from Contingency Tables, and the Calculation of P. *Journal of the Royal Statistical Society* **85**, (1922).
- 15. Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* **581**, (2020).
- Buniello, A. *et al.* The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res* 47, (2019).
- Tyrmi, J. S. *et al.* Leveraging Northern European population history: Novel lowfrequency variants for polycystic ovary syndrome. *Human Reproduction* **37**, (2022).
- Tammi, S. *et al.* Accurate multi-population imputation of MICA, MICB, HLA-E, HLA-F and HLA-G alleles from genome SNP data. *bioRxiv* 2023.12.05.570226 (2023) doi:10.1101/2023.12.05.570226.

- 19. Yu, C. *et al.* TBPL2/TFIIA complex establishes the maternal transcriptome through oocyte-specific promoter usage. *Nat Commun* **11**, (2020).
- 20. Gazdag, E. *et al.* TBP2 is essential for germ cell development by regulating transcription and chromatin condensation in the oocyte. *Genes Dev* **23**, (2009).
- Du, T. *et al.* Compound heterozygous mutations in TBPL2 were identified in an infertile woman with impaired ovarian folliculogenesis. *J Assist Reprod Genet* **40**, (2023).
- Tora, L. & Vincent, S. D. What defines the maternal transcriptome? Biochemical Society Transactions vol. 49 Preprint at https://doi.org/10.1042/BST20201125 (2021).
- 23. Wang, Y. *et al.* A homozygous missense mutation in TBPL2 is associated with oocyte maturation arrest and degeneration. *Clin Genet* **100**, (2021).
- 24. Hochler, H. *et al.* The Impact of Advanced Maternal Age on Pregnancy Outcomes: A Retrospective Multicenter Study. *J Clin Med* **12**, (2023).
- 25. Heffner, L. J. Advanced Maternal Age How Old Is Too Old? *New England Journal of Medicine* **351**, (2004).
- 26. Maheshwari, A., Hamilton, M. & Bhattacharya, S. Effect of female age on the diagnostic categories of infertility. *Human Reproduction* **23**, (2008).
- 27. Mars, N. *et al.* The role of polygenic risk and susceptibility genes in breast cancer over the course of life. *Nat Commun* **11**, (2020).
- Sharma, S. Natural killer cells and regulatory T cells in early pregnancy loss. *International Journal of Developmental Biology* vol. 58 Preprint at https://doi.org/10.1387/ijdb.140109ss (2014).

List of Figures

List of Tables

Table 1: Basic characteristics of the study cohort. 4
Table 2: Independent GWAS hits and their representative variants identified by
either additive or recessive model. The lead variant from the recessive and the
additive models at the shared locus (PKHD1L1) are within the same credible set (LD
= 1)11
Table 3: Genetic correlations with female infertility (rg) and enrichment of female
infertility cases (Enrichment) among four underlying disorders for female
reproduction16

Ethics statement

Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.

The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/283/6.02.00/2019, THL/2222/6.02.00/2018, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA KELA 2/522/2020, 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics Finland (permit TK/143/07.03.00/2020 numbers: TK-53-1041-17 (earlier TK-53-90-20) and

TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019.

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 11 include: THL Biobank BB2017 55, BB2017 111, BB2018 19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, BB2021_65, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, HUS/430/2021 §28, §29, HUS/150/2022 §12, §13, §14, §15, §16, §17, §18, §23, §58, §59, HUS/128/2023 §18, Auria Biobank AB17-5154 and amendment #1 (August 17 2020) and amendments BB_2021-0140, BB_2021-0156 (August 26 2021, Feb 2 2022), BB_2021-0169, BB_2021-0179, BB_2021-0161, AB20-5926 and amendment #1 (April 23 2020) and it's modifications (Sep 22 2021), BB 2022-0262, BB 2022-0256, Biobank Borealis of Northern Finland_2017_1013, 2021_5010, 2021 5010 Amendment, 2021 5018, 2021 5018 Amendment, 2021 5015, 2021 5015 Amendment, 2021 5015 Amendment 2, 2021 5023, 2021 5023 Amendment, 2021 5023 Amendment 2, 2021 5017, 2021 5017 Amendment, 2022 6001, Amendment, 2022 6001 Amendment, 2022_6006 Amendment, 2022_6006 2022_6006 Amendment_2, BB22-0067, 2022_0262, 2022_0262 Amendment, Biobank of Eastern Finland 1186/2018 and amendment 22§/2020, 53§/2021, 13§/2022, 14§/2022, 15§/2022, 27§/2022, 28§/2022, 29§/2022, 33§/2022, 35§/2022, 36§/2022, 37§/2022, 39§/2022, 7§/2023, 32§/2023, 33§/2023, 34§/2023, 35§/2023, 36§/2023, 37§/2023, 38§/2023, 39§/2023, 40§/2023, 41§/2023, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), BB2021-0140 8§/2021, 9§/2021, §9/2022, §10/2022, §12/2022, 13§/2022, §20/2022,

§21/2022, §22/2022, §23/2022, 28§/2022, 29§/2022, 30§/2022, 31§/2022, 32§/2022, 38§/2022, 40§/2022, 42§/2022, 1§/2023, Central Finland Biobank 1-2017, BB_2021-0161, BB_2021-0169, BB_2021-0179, BB_2021-0170, BB_2022-0256, BB_2022-0262, BB22-0067, Decision allowing to continue data processing until 31st Aug 2024 for projects: BB_2021-0179, BB22-0067,BB_2022-0262, BB_2021-0170, BB_2021-0164, BB_2021-0161, and BB_2021-0169, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020, Finnish Hematological Registry and Clinical Biobank decision 18th June 2021, Arctic biobank P0844: ARC_2021_1001.

Declaration of interests

The authors declare no competing interests.

Data and code availability

Individual level data: The Finnish biobank data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB. Finnish Health register data can be applied from Findata (<u>https://findata.fi/en/data/</u>).

Summary statistics: Summary statistics from each data release will be made publicly available after a one year embargo period and can be accessed freely from: www.finngen.fi/en/access_results.

Acknowledgements

We want to acknowledge the participants and investigators of the FinnGen study. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-jaopetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Tervevstalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank (https://www.oulu.fi/en/university/faculties-and-units/facultymedicine/northern-finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members BBMRI.fi of infrastructure (https://www.bbmri-eric.eu/national-

nodes/finland/). Finnish Biobank Cooperative -FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be

accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed

by FINBB.

Full list of FinnGen authors

Full Name	Affiliation	E-mail		
	Institute for Molecular Medicine Finland (FIMM),			
Aarno Palotie	HiLIFE, University of Helsinki, Helsinki, Finland;	aarno.palotie@helsinki.fi		
	Broad Institute of MIT and Harvard; Massachusetts	anne puloto e noionnain		
	General Hospital			
	Institute for Molecular Medicine Finland (FIMM),			
Mark Daly	HiLIFE, University of Helsinki, Helsinki, Finland;	mark.daly@helsinki.fi		
Mark Daly	Broad Institute of MIT and Harvard; Massachusetts	mark.daly@helsinki.n		
	General Hospital			
Bridget Riley-Gills	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com		
Howard Jacob	Abbvie, Chicago, IL, United States	howard.jacob@abbvie.com		
Dirk Paul	Astra Zeneca, Cambridge, United Kingdom	dirk.paul@astrazeneca.com		
Slavé Petrovski	Astra Zeneca, Cambridge, United Kingdom	slav.petrovski@astrazeneca.com		
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com		
Sally John	Biogen, Cambridge, MA, United States	sally.john@biogen.com		
	Boehringer Ingelheim, Ingelheim am Rhein,			
George Okafo	Germany	george.okafo@boehringer-ingelheim.com		
Robert Plenge	Bristol Myers Squibb, New York, NY, United States	robert.plenge@bms.com		
Joseph Maranville	Bristol Myers Squibb, New York, NY, United States	joseph.maranville@bms.com		
Mark McCarthy	Genentech, San Francisco, CA, United States	mccarthy.mark@gene.com		
Margaret G. Ehm	GlaxoSmithKline, Collegeville, PA, United States	meg.g.ehm@gsk.com		
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com		
Simonne Longerich	Merck, Kenilworth, NJ, United States	simonne.longerich@merck.com		
Anders Mälarstig	Pfizer, New York, NY, United States	anders.malarstig@pfizer.com		
	Translational Sciences, Sanofi R&D, Framingham,			
Katherine Klinger	MA, USA	katherine.klinger@sanofi.com		
Olement Obstalaia	Translational Sciences, Sanofi R&D, Framingham,	alamant akatalain @aanati aan		
Clement Chatelain	MA, USA	clement.chatelain@sanofi.com		
Matthew	Translational Sciences, Sanofi R&D, Framingham,			
Matthias Gossel	MA, USA	matthias.gossel@sanofi.com		
Karal Estuada	Maze Therapeutics, San Francisco, CA, United			
Karol Estrada	States	kestrada@mazetx.com		
Dahad Oral and	Maze Therapeutics, San Francisco, CA, United			
Robert Graham	States	rgraham@mazetx.com		
Dawn Waterworth	Janssen Research & Development, LLC, Spring			
		dwaterwo@its.jnj.com		

Jaakko Kaprio		jaakko.kaprio@helsinki.fi
laakko Kanrio	Institute for Molecular Medicine Finland (FIMM),	iaakko kanrio@helsinki fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Petri Virolainen	Auria Biobank / University of Turku / Hospital	petri.virolainen@tyks.fi
	District of Southwest Finland, Turku, Finland	
Antti Hakanen	Auria Biobank / University of Turku / Hospital	antti.hakanen@tyks.fi
	District of Southwest Finland, Turku, Finland	
Terhi Kilpi	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	terhi.kilpi@thl.fi
	THL Biobank / Finnish Institute for Health and	
Markus Perola	Welfare (THL), Helsinki, Finland	markus.perola@thl.fi
	Finnish Red Cross Blood Service / Finnish	
Jukka Partanen	Hematology Registry and Clinical Biobank,	jukka.partanen@veripalvelu.fi
	Helsinki, Finland	Juna.pananen evenpaiveid.n
	Helsinki Biobank / Helsinki University and Hospital	
Anne Pitkäranta	District of Helsinki and Uusimaa, Helsinki	anne.pitkaranta@hus.fi
	Helsinki Biobank / Helsinki University and Hospital	
Taneli Raivio	District of Helsinki and Uusimaa, Helsinki	taneli.raivio@hus.fi
	Northern Finland Biobank Borealis / University of	
Jani Tikkanen	Oulu / Northern Ostrobothnia Hospital District,	jani.tikkanen@ppshp.fi
	Oulu, Finland	
	Northern Finland Biobank Borealis / University of	
Raisa Serpi	Oulu / Northern Ostrobothnia Hospital District,	raisa.serpi@ppshp.fi
	Oulu, Finland	
	Finnish Clinical Biobank Tampere / University of	
Tarja Laitinen	Tampere / Pirkanmaa Hospital District, Tampere,	tarja.laitinen@pshp.fi
	Finland	
	Biobank of Eastern Finland / University of Eastern	
Veli-Matti Kosma	Finland / Northern Savo Hospital District, Kuopio,	veli-matti.kosma@uef.fi
	Finland	
	Central Finland Biobank / University of Jyväskylä /	
	Central Finland Health Care District, Jyväskylä,	jari.laukkanen@ksshp.fi
Jari Laukkanen	ochtrai i iniana i icalari oare District, oyvaskyla,	
Jari Laukkanen	Finland	

Raimo Pakkanen	Business Finland, Helsinki, Finland	raimo.pakkanen@businessfinland.fi
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com
Ioanna Tachmazidou	Astra Zeneca, Cambridge, United Kingdom	ioanna.tachmazidou@astrazeneca.com
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen@biogen.com
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com
Zhihao Ding	Boehringer Ingelheim, Ingelheim am Rhein, Germany	zhihao.ding@boehringer-ingelheim.com
Marc Jung	Boehringer Ingelheim, Ingelheim am Rhein, Germany	marc_oliver.jung@boehringer-
Hanati Tuoken	Boehringer Ingelheim, Ingelheim am Rhein, Germany	hanati.tuoken@boehringer-ingelheim.cor
Shameek Biswas	Bristol Myers Squibb, New York, NY, United States	Shameek.Biswas@bms.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Margaret G. Ehm	GlaxoSmithKline, Collegeville, PA, United States	meg.g.ehm@gsk.com
David Pulford	GlaxoSmithKline, Stevenage, United Kingdom	david.x.pulford@gsk.com
Neha Raghavan	Merck, Kenilworth, NJ, United States	neha.raghavan@merck.com
Adriana Huertas-Vazquez	Merck, Kenilworth, NJ, United States	adriana.huertas.vazquez@merck.com
Jae-Hoon Sul	Merck, Kenilworth, NJ, United States	jae.hoon.sul@merck.com
Anders Mälarstig	Pfizer, New York, NY, United States	anders.malarstig@pfizer.com
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com
Åsa Hedman	Pfizer, New York, NY, United States	asa.hedman@pfizer.com
Katherine Klinger	Translational Sciences, Sanofi R&D, Framingham, MA, USA	katherine.klinger@sanofi.com
Robert Graham	Maze Therapeutics, San Francisco, CA, United States	rgraham@mazetx.com
Manuel Rivas	Maze Therapeutics, San Francisco, CA, United States	mrivas@mazetx.com
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com
Nicole Renaud	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	nicole.renaud@novartis.com
Ma´en Obeidat	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	maen.obeidat@novartis.com
Jonathan Chung	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	jonathan.chung@novartis.com
Jonas Zierer	Novartis Institutes for BioMedical Research, Cambridge, MA, United States	jonas.zierer@novartis.com

Mari Niami	Novartis Institutes for BioMedical Research,	mari niami@navartia aam
Mari Niemi	Cambridge, MA, United States	mari.niemi@novartis.com
Samuli Ripatti	Institute for Molecular Medicine Finland (FIMM),	samuli.ripatti@helsinki.fi
Cantan rapata	HiLIFE, University of Helsinki, Helsinki, Finland	
Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of	johanna.schleutker@utu.fi
	Southwest Finland, Turku, Finland	
Markus Perola	THL Biobank / Finnish Institute for Health and	markus.perola@thl.fi
	Welfare (THL), Helsinki, Finland	
	Finnish Red Cross Blood Service / Finnish	
Mikko Arvas	Hematology Registry and Clinical Biobank,	mikko.arvas@veripalvelu.fi
	Helsinki, Finland	
Olli Carpén	Helsinki Biobank / Helsinki University and Hospital	olli.carpen@helsinki.fi
	District of Helsinki and Uusimaa, Helsinki	
	Northern Finland Biobank Borealis / University of	
Reetta Hinttala	Oulu / Northern Ostrobothnia Hospital District,	reetta.hinttala@oulu.fi
	Oulu, Finland	
	Northern Finland Biobank Borealis / University of	
Johannes Kettunen	Oulu / Northern Ostrobothnia Hospital District,	johannes.kettunen@oulu.fi
	Oulu, Finland	
	Biobank of Eastern Finland / University of Eastern	
Arto Mannermaa	Finland / Northern Savo Hospital District, Kuopio,	arto.mannermaa@uef.fi
	Finland	
Katriina Aalto-Setälä	Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland	katriina.aalto-setala@tuni.fi
	Finnish Clinical Biobank Tampere / University of	
Mika Kähönen	Tampere / Pirkanmaa Hospital District, Tampere,	mika.kahonen@uta.fi
	Finland	
	Central Finland Biobank / University of Jyväskylä /	
Jari Laukkanen	Central Finland Health Care District, Jyväskylä,	jari.laukkanen@ksshp.fi
	Finland	
Johanna Mäkelä	FINBB - Finnish biobank cooperative	johanna.makela@finbb.fi
Reetta Kälviäinen	Northern Savo Hospital District, Kuopio, Finland	reetta.kalviainen@kuh.fi
Valtteri Julkunen	Northern Savo Hospital District, Kuopio, Finland	valtteri.julkunen@kuh.fi
Hilkka Soininen	Northern Savo Hospital District, Kuopio, Finland	hilkka.soininen@uef.fi
Anne Remes	Northern Ostrobothnia Hospital District, Oulu,	anno romos@culu fi
Anne Remes	Finland	anne.remes@oulu.fi
Mikko Hiltunen	University of Eastern Finland, Kuopio, Finland	mikko.hiltunen@uef.fi
Jukka Peltola	Pirkanmaa Hospital District, Tampere, Finland	jukka.peltola@pshp.fi
Minna Raivio	Hospital District of Helsinki and Uusimaa, Helsinki,	minna.raivio@geri.fi

	Finland	
Pentti Tienari	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pentti.tienari@hus.fi
Juha Rinne	Hospital District of Southwest Finland, Turku, Finland	juha.rinne@tyks.fi
Roosa Kallionpää	Hospital District of Southwest Finland, Turku, Finland	roosa.kallionpaa@tyks.fi
Juulia Partanen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland	juulia.partanen@helsinki.fi
Adam Ziemann	Abbvie, Chicago, IL, United States	adam.ziemann@abbvie.com
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Susan Eaton	Biogen, Cambridge, MA, United States	susan.eaton@biogen.com
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com
Sanni Lahdenperä	Biogen, Cambridge, MA, United States	sanni.lahdenpera@biogen.com
Shameek Biswas	Bristol Myers Squibb, New York, NY, United States	shameek.biswas@bms.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Edmond Teng	Genentech, San Francisco, CA, United States	teng.edmond@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Fanli Xu	GlaxoSmithKline, Brentford, United Kingdom	chun-fang.2.xu@gsk.com
David Pulford	GlaxoSmithKline, Stevenage, United Kingdom	david.x.pulford@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Laura Addis	GlaxoSmithKline, Brentford, United Kingdom	laura.x.addis@gsk.com
John Eicher	GlaxoSmithKline, Brentford, United Kingdom	john.d.eicher@gsk.com
Qingqin S Li	Janssen Research & Development, LLC, Titusville, NJ 08560, United States	QLi2@its.jnj.com
Karen He	Janssen Research & Development, LLC, Spring House, PA, United States	khe2@its.jnj.com
Ekaterina Khramtsova	Janssen Research & Development, LLC, Spring House, PA, United States	ekhramts@its.jnj.com
Neha Raghavan	Merck, Kenilworth, NJ, United States	neha.raghavan@merck.com
Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	martti.farkkila@hus.fi
Jukka Koskela	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	jukka.koskela@helsinki.fi
Sampsa Pikkarainen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	sampsa.pikkarainen@hus.fi
Airi Jussila	Pirkanmaa Hospital District, Tampere, Finland	airi.jussila@pshp.fi
Katri Kaukinen	Pirkanmaa Hospital District, Tampere, Finland	katri.kaukinen@tuni.fi

Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi
Johanna Huhtakangas	Northern Ostrobothnia Hospital District, Oulu, Finland	johanna.huhtakangas@kuh.fi
Oili Kaipiainen-Seppänen	Northern Savo Hospital District, Kuopio, Finland	oili.kaipiainen-seppanen@kuh.fi
Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland	laura.pirila@fimnet.fi,laura.pirila@tyks.fi
Pia Isomäki	Pirkanmaa Hospital District, Tampere, Finland	pia.isomaki@pshp.fi
Antti Palomäki	Hospital District of Southwest Finland, Turku, Finland	ajpalo@utu.fi
Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	kari.eklund@hus.fi
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.miller@pfizer.com
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala@pfizer.com
Jason Miller	Merck, Kenilworth, NJ, United States	jason.miller4@merck.com
Meijian Guan	House, PA, United States	mguan4@its.jnj.com
Meilien Curr	Janssen Research & Development, LLC, Spring	
Amy Hart	Janssen Research & Development, LLC, Spring House, PA, United States	ahart13@its.jnj.com
Linda McCarthy	GlaxoSmithKline, Brentford, United Kingdom	linda.c.mccarthy@gsk.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Tim Lu	Genentech, San Francisco, CA, United States	lut8@gene.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
	General Hospital	
Mark Daly	Broad Institute of MIT and Harvard; Massachusetts	mark.daly@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland;	
Markku Voutilainen	Finland Institute for Molecular Medicine, Finland (FIMM),	markku.voutilainen@tyks.fi
Mikko Kiviniemi	Northern Savo Hospital District, Kuopio, Finland Hospital District of Southwest Finland, Turku,	mikko.kiviniemi@kuh.fi
Timo Blomster	Finland	timo.blomster@ppshp.fi

Apinya Lertratanakul	Abbvie, Chicago, IL, United States	apinya.lertratanakul@abbvie.com
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Coralie Viollet	AstraZeneca, Cambridge, United Kingdom	coralie.viollet@astrazeneca.com
Marla Hochfeld	Bristol Myers Squibb, New York, NY, United States	mhochfeld@celgene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Jorge Esparza Gordillo	GlaxoSmithKline, Brentford, United Kingdom	jorge.x.esparza-gordillo@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Devue Wiete events	Janssen Research & Development, LLC, Spring	durada a un Qida ini a an
Dawn Waterworth	House, PA, United States	dwaterwo@its.jnj.com
Fabiana Farias	Merck, Kenilworth, NJ, United States	fabiana.farias@merck.com
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala@pfizer.com
Nan Bing	Pfizer, New York, NY, United States	nan.bing@pfizer.com
Xinli Hu	Pfizer, New York, NY, United States	xinli.hu@pfizer.com
Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen@pshp.fi
Margit Pelkonen	Northern Savo Hospital District, Kuopio, Finland	margit.pelkonen@kuh.fi
	Hospital District of Helsinki and Uusimaa, Helsinki,	
Paula Kauppi	Finland	paula.kauppi@hus.fi
	University of Gothenburg, Gothenburg, Sweden/	
Hannu Kankaanranta	Seinäjoki Central Hospital, Seinäjoki, Finland/	hannu.kankaanranta@tuni.fi
	Tampere University, Tampere, Finland	
	Northern Ostrobothnia Hospital District, Oulu,	
Terttu Harju	Finland	terttu.harju@oulu.fi
	Hospital District of Southwest Finland, Turku,	
Riitta Lahesmaa	Finland	rilahes@utu.fi
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Coralie Viollet	AstraZeneca, Cambridge, United Kingdom	coralie.viollet@astrazeneca.com
Susan Eaton	Biogen, Cambridge, MA, United States	susan.eaton@biogen.com
Hubert Chen	Genentech, San Francisco, CA, United States	chenh37@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Joanna Betts	GlaxoSmithKline, Brentford, United Kingdom	joanna.c.betts@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Rajashree Mishra	GlaxoSmithKline, Brentford, United Kingdom	rajashree.x.mishra@gsk.com
Majd Mouded	Novartis, Basel, Switzerland	majd.mouded@novartis.com
Debby Ngo	Novartis, Basel, Switzerland	debby.ngo@novartis.com
Teemu Niiranen	Finnish Institute for Health and Welfare (THL),	teemu.niiranen@thl.fi
	Helsinki, Finland	

Felix Vaura	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	fechva@utu.fi
Veikko Salomaa	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	veikko.salomaa@thl.fi
Kaj Metsärinne	Hospital District of Southwest Finland, Turku, Finland	kaj.metsarinne@tyks.fi
Jenni Aittokallio	Hospital District of Southwest Finland, Turku, Finland	jemato@utu.fi
Mika Kähönen	Pirkanmaa Hospital District, Tampere, Finland	mika.kahonen@uta.fi
Jussi Hernesniemi	Pirkanmaa Hospital District, Tampere, Finland	jussi.hernesniemi@tuni.fi
Daniel Gordin	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	daniel.gordin@hus.fi
Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	juha.sinisalo@hus.fi
Marja-Riitta Taskinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	marja-riitta.taskinen@helsinki.fi
Tiinamaija Tuomi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tiinamaija.tuomi@hus.fi
Timo Hiltunen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	timo.hiltunen@hus.fi
Jari Laukkanen	Central Finland Health Care District, Jyväskylä, Finland	jari.laukkanen@ksshp.fi
Amanda Elliott	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute, Cambridge, MA, USA and Massachusetts General Hospital, Boston, MA, USA	aelliott@broadinstitute.org
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi
Sanni Ruotsalainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	sanni.ruotsalainen@helsinki.fi
Dirk Paul	Astra Zeneca, Cambridge, United Kingdom	dirk.paul@astrazeneca.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom	audrey.y.chu@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Dermot Reilly	Janssen Research & Development, LLC, Boston, MA, United States	dreill11@its.jnj.com
Mike Mendelson	Novartis, Boston, MA, United States	mike.mendelson@novartis.com

Jaakko Parkkinen	Pfizer, New York, NY, United States	jaakko.parkkinen@pfizer.com
Melissa Miller	Pfizer, New York, NY, United States	melissa.r.miller@pfizer.com
Tuomo Meretoja	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuomo.meretoja@hus.fi
Heikki Joensuu	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	heikki.joensuu@hus.fi
Olli Carpén	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	olli.carpen@helsinki.fi
Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	johanna.mattson@hus.fi
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.salminen@hus.fi
Annika Auranen	Pirkanmaa Hospital District , Tampere, Finland	anaura@utu.fi
Peeter Karihtala	Northern Ostrobothnia Hospital District, Oulu, Finland	peeter.karihtala@oulu.fi
Päivi Auvinen	Northern Savo Hospital District, Kuopio, Finland	paivi.auvinen@kuh.fi
Klaus Elenius	Hospital District of Southwest Finland, Turku, Finland	klaus.elenius@utu.fi
Johanna Schleutker	Hospital District of Southwest Finland, Turku, Finland	johanna.schleutker@utu.fi
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	esa.pitkanen@helsinki.fi
Nina Mars	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@helsinki.fi
Relja Popovic	Abbvie, Chicago, IL, United States	relja.popovic@abbvie.com
Jeffrey Waring	Abbvie, Chicago, IL, United States	jeff.waring@abbvie.com
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com
Margarete Fabre	AstraZeneca, Cambridge, United Kingdom	margarete.fabre@astrazeneca.com
Jennifer Schutzman	Genentech, San Francisco, CA, United States	schutzman.jennifer@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom	diptee.a.kulkarni@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
Alessandro Porello	Janssen Research & Development, LLC, Spring	APorrell@ITS.JNJ.com

	House, PA, United States	
Andrey Loboda	Merck, Kenilworth, NJ, United States	andrey_loboda@merck.com
Heli Lehtonen	Pfizer, New York, NY, United States	heli.lehtonen@pfizer.com
Stefan McDonough	Pfizer, New York, NY, United States	stefan.McDonough@pfizer.com
Sauli Vuoti	Janssen-Cilag Oy, Espoo, Finland	svuoti@its.jnj.com
	Northern Savo Hospital District, Kuopio, Finland;	
Kai Kaarniranta	Department of Molecular Genetics, University of	kai.kaarniranta@uef.fi
	Lodz, Lodz, Poland	
	Helsinki University Hospital and University of	
Joni A Turunen	Helsinki, Helsinki, Finland; Eye Genetics Group,	joni.turunen@helsinki.fi
	Folkhälsan Research Center, Helsinki, Finland	
	Hospital District of Helsinki and Uusimaa, Helsinki,	
Terhi Ollila	Finland	terhi.ollila@hus.fi
Hannu Uusitalo	Pirkanmaa Hospital District, Tampere, Finland	hannu.uusitalo@tuni.fi
		าสากน.นนอเนียงซ เนที่ไ.ท
Juha Karjalainen	Institute for Molecular Medicine Finland (FIMM),	juha.karjalainen@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Esa Pitkänen	Institute for Molecular Medicine Finland (FIMM),	esa.pitkanen@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Mengzhen Liu	Abbvie, Chicago, IL, United States	mengzhen.liu@abbvie.com
Heiko Runz	Biogen, Cambridge, MA, United States	heiko.runz@biogen.com
Stephanie Loomis	Biogen, Cambridge, MA, United States	stephanie.loomis@biogen.com
Erich Strauss	Genentech, San Francisco, CA, United States	strauss.erich@gene.com
Natalie Bowers	Genentech, San Francisco, CA, United States	bowersn1@gene.com
Hao Chen	Genentech, San Francisco, CA, United States	haoc@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
K	Northern Ostrobothnia Hospital District, Oulu,	
Kaisa Tasanen	Finland	kaisa.tasanen-maatta@oulu.fi
	Northern Ostrobothnia Hospital District, Oulu,	
Laura Huilaja	Finland	laura.huilaja@oulu.fi
	Hospital District of Helsinki and Uusimaa, Helsinki,	
Katariina Hannula-Jouppi	Finland	katariina.hannula-jouppi@hus.fi
Teea Salmi	Pirkanmaa Hospital District, Tampere, Finland	teea.salmi@pshp.fi
	Hospital District of Southwest Finland, Turku,	
Sirkku Peltonen	Finland	sipelto@utu.fi
	Hospital District of Southwest Finland, Turku,	
Leena Koulu	Finland	leena.koulu@tyks.fi
Nizar Smaoui	Abbvie, Chicago, IL, United States	nizar.smaoui@abbvie.com
Fedik Rahimov	Abbvie, Chicago, IL, United States	fedik.rahimov@abbvie.com
Anne Lehtonen	Abbvie, Chicago, IL, United States	anne.lehtonen@abbvie.com

David Choy	Genentech, San Francisco, CA, United States	choy.david@gene.com
Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States	dwaterwo@its.jnj.com
Kirsi Kalpala	Pfizer, New York, NY, United States	kirsi.kalpala@pfizer.com
Ying Wu	Pfizer, New York, NY, United States	ying.wu3@pfizer.com
Pirkko Pussinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pirkko.pussinen@helsinki.fi
Aino Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	aino.m.salminen@helsinki.fi
Tuula Salo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	tuula.salo@helsinki.fi
David Rice	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	david.rice@helsinki.fi
Pekka Nieminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	pekka.nieminen@helsinki.fi
Ulla Palotie	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	ulla.palotie@helsinki.fi
Maria Siponen	Northern Savo Hospital District, Kuopio, Finland	maria.siponen@uef.fi
Liisa Suominen	Northern Savo Hospital District, Kuopio, Finland	liisa.suominen@uef.fi
Päivi Mäntylä	Northern Savo Hospital District, Kuopio, Finland	paivi.mantyla@uef.fi
Ulvi Gursoy	Hospital District of Southwest Finland, Turku, Finland	ulvi.gursoy@utu.fi
Vuokko Anttonen	Northern Ostrobothnia Hospital District, Oulu, Finland	vuokko.anttonen@oulu.fi
Kirsi Sipilä	Research Unit of Oral Health Sciences Faculty of Medicine, University of Oulu, Oulu, Finland; Medical Research Center, Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland	kirsi.sipila@oulu.fi
Rion Pendergrass	Genentech, San Francisco, CA, United States	pendergrass.sarah@gene.com
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hannele.laivuori@helsinki.fi
Venla Kurra	Pirkanmaa Hospital District, Tampere, Finland	venla.kurra@tuni.fi
Laura Kotaniemi-Talonen	Pirkanmaa Hospital District, Tampere, Finland	laura.kotaniemi-talonen@tuni.fi
Oskari Heikinheimo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	oskari.heikinheimo@helsinki.fi
llkka Kalliala	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	ilkka.kalliala@hus.fi
	Hospital District of Helsinki and Uusimaa, Helsinki,	

	Finland	
Varpu Jokimaa	Hospital District of Southwest Finland, Turku, Finland	varpu.jokimaa@utu.fi
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland	Johannes.Kettunen@oulu.fi
Marja Vääräsmäki	Northern Ostrobothnia Hospital District, Oulu, Finland	marja.vaarasmaki@oulu.fi
Outi Uimari	Northern Ostrobothnia Hospital District, Oulu, Finland	outi.uimari@oulu.fi
Laure Morin-Papunen	Northern Ostrobothnia Hospital District, Oulu, Finland	lmp@cc.oulu.fi
Maarit Niinimäki	Northern Ostrobothnia Hospital District, Oulu, Finland	maarit.niinimaki@oulu.fi
Terhi Piltonen	Northern Ostrobothnia Hospital District, Oulu, Finland	terhi.piltonen@oulu.fi
Katja Kivinen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	katja.kivinen@helsinki.fi
Elisabeth Widen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elisabeth.widen@helsinki.fi
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	taru.tukiainen@helsinki.fi
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi
Mark Daly	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard; Massachusetts General Hospital	mark.daly@helsinki.fi
Niko Välimäki	University of Helsinki, Helsinki, Finland	niko.valimaki@helsinki.fi
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkonen@jyu.fi
Jaakko Tyrmi	University of Oulu, Oulu, Finland / University of Tampere, Tampere, Finland	jaakko.tyrmi@oulu.fi
Heidi Silven	University of Oulu, Oulu, Finland	heidi.silven@student.oulu.fi
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@oulu.fi
Riikka Arffman	University of Oulu, Oulu, Finland	riikka.arffman@oulu.fi
Susanna Savukoski	University of Oulu, Oulu, Finland	susanna.savukoski@oulu.fi
Triin Laisk	Estonian biobank, Tartu, Estonia	triin.laisk@ut.ee
Natalia Pujol	Estonian biobank, Tartu, Estonia	natalia.pujolgualdo@oulu.fi
Mengzhen Liu	Abbvie, Chicago, IL, United States	mengzhen.liu@abbvie.com
Bridget Riley-Gillis	Abbvie, Chicago, IL, United States	bridget.rileygillis@abbvie.com

Rion Pendergrass	Genentech, San Francisco, CA, United States	penders2@gene.com
Janet Kumar	GlaxoSmithKline, Collegeville, PA, United States	janet.x.kumar@gsk.com
Kirsi Auro	GlaxoSmithKline, Espoo, Finland	kirsi.m.auro@gsk.com
liris Hovatta	University of Helsinki, Finland	iiris.hovatta@helsinki.fi
Chia-Yen Chen	Biogen, Cambridge, MA, United States	chiayen.chen@biogen.com
Erkki Isometsä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	erkki.isometsa@hus.fi
Hanna Ollila	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollila@helsinki.fi
Jaana Suvisaari	Finnish Institute for Health and Welfare (THL), Helsinki, Finland	jaana.suvisaari@thl.fi
Antti Mäkitie	Department of Otorhinolaryngology - Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland	antti.makitie@helsinki.fi
Argyro Bizaki-Vallaskangas	Pirkanmaa Hospital District, Tampere, Finland	argyro.bizaki-vallaskangas@tuni.fi
Sanna Toppila-Salmi	University of Eastern Finland and Kuopio University Hospital, Department of Otorhinolaryngology, Kuopio, Finland and Department of Allergy, Helsinki University Hospital and University of Helsinki, Finland	sanna.salmi@helsinki.fi
Tytti Willberg	Hospital District of Southwest Finland, Turku, Finland	tytti.willberg@tyks.fi
Elmo Saarentaus	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	elmo.saarentaus@helsinki.fi
Antti Aarnisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	antti.aarnisalo@hus.fi
Eveliina Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland	eveliina.e.salminen@hus.fi
Elisa Rahikkala	Northern Ostrobothnia Hospital District, Oulu, Finland	elisa.rahikkala@ppshp.fi
Johannes Kettunen	Northern Ostrobothnia Hospital District, Oulu, Finland	johannes.kettunen@oulu.fi
Kristiina Aittomäki	Department of Medical Genetics, Helsinki University Central Hospital, Helsinki, Finland	kristiina.aittomaki@helsinki.fi
Fredrik Åberg	Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki University, Helsinki, Finland	fredrik.aberg@helsinki.fi
Mitja Kurki	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland;	mkurki@broadinstitute.org

	Broad Institute, Cambridge, MA, United States	
	Institute for Molecular Medicine Finland (FIMM),	
Samuli Ripatti	HiLIFE, University of Helsinki, Helsinki, Finland	samuli.ripatti@helsinki.fi
	Institute for Molecular Medicine, Finland (FIMM),	
	HiLIFE, University of Helsinki, Helsinki, Finland;	
Mark Daly	Broad Institute of MIT and Harvard; Massachusetts	mark.daly@helsinki.fi
	General Hospital	
	Institute for Molecular Medicine Finland (FIMM),	
Juha Karjalainen	HiLIFE, University of Helsinki, Helsinki, Finland	juha.karjalainen@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
	HiLIFE, University of Helsinki, Helsinki, Finland;	
Aki Havulinna	Finnish Institute for Health and Welfare (THL),	aki.havulinna@helsinki.fi
	Helsinki, Finland	
	Institute for Molecular Medicine Finland (FIMM),	
Juha Mehtonen	HiLIFE, University of Helsinki, Helsinki, Finland	juha.mehtonen@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Priit Palta	HiLIFE, University of Helsinki, Helsinki, Finland	priit.palta@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Shabbeer Hassan		shabbeer.hassan@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland (FIMM),	pietro.dellabriottaparolo@helsinki.fi
14/	HiLIFE, University of Helsinki, Helsinki, Finland	
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broadinstitute.org
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@broadinstitute.org
Shabbeer Hassan	Institute for Molecular Medicine Finland (FIMM),	shabbeer.hassan@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM),	susanna.lemmela@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Manuel Rivas	University of Stanford, Stanford, CA, United States	mrivas@stanford.edu
Aarno Palotie	Institute for Molecular Medicine Finland (FIMM),	aarno.palotie@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Aoxing Liu	Institute for Molecular Medicine Finland (FIMM),	aoxing.liu@helsinki.fi
5	HiLIFE, University of Helsinki, Helsinki, Finland	J
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM),	arto.lehisto@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Andrea Ganna	Institute for Molecular Medicine Finland (FIMM),	aganna@hroadinstitute.org
	HiLIFE, University of Helsinki, Helsinki, Finland	aganna@broadinstitute.org
Vincent Llorons	Institute for Molecular Medicine Finland (FIMM),	vincent.llorens@helsinki.fi
Vincent Llorens	HiLIFE, University of Helsinki, Helsinki, Finland	
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM),	hannele.laivuori@helsinki.fi

	HiLIFE, University of Helsinki, Helsinki, Finland	
Taru Tukiainen	Institute for Molecular Medicine Finland (FIMM),	taru.tukiainen@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM),	mary.reeve@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	mary.recve enclonia.in
	Institute for Molecular Medicine Finland (FIMM),	
Henrike Heyne	HiLIFE, University of Helsinki, Helsinki, Finland	hheyne@broadinstitute.org
	Institute for Molecular Medicine Finland (FIMM),	
Nina Mars	HiLIFE, University of Helsinki, Helsinki, Finland	nina.mars@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Joel Rämö	HiLIFE, University of Helsinki, Helsinki, Finland	joel.ramo@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Elmo Saarentaus	HiLIFE, University of Helsinki, Helsinki, Finland	elmo.saarentaus@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Hanna Ollila	HiLIFE, University of Helsinki, Helsinki, Finland	hanna.m.ollila@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Rodos Rodosthenous		rodos.rodosthenous@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Satu Strausz	Institute for Molecular Medicine Finland (FIMM),	satu.strausz@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Tuula Palotie	University of Helsinki and Hospital District of	tuula.palotie@helsinki.fi
	Helsinki and Uusimaa, Helsinki, Finland	
Kimmo Palin	University of Helsinki, Helsinki, Finland	kimmo.palin@helsinki.fi
Javier Garcia-Tabuenca	University of Tampere, Tampere, Finland	javier.graciatabuenca@tuni.fi
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola@tuni.fi
Tuomo Kiiskinen	Institute for Molecular Medicine Finland (FIMM),	tuomo kiiskinon@holoinki fi
	HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskinen@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Jiwoo Lee	HiLIFE, University of Helsinki, Helsinki, Finland;	jiwoo.lee@helsinki.fi
	Broad Institute, Cambridge, MA, United States	
	Institute for Molecular Medicine Finland (FIMM),	
Kristin Tsuo	HiLIFE, University of Helsinki, Helsinki, Finland;	kristintsuo@fas.harvard.edu
	Broad Institute, Cambridge, MA, United States	
	Institute for Molecular Medicine Finland (FIMM),	
	HiLIFE, University of Helsinki, Helsinki, Finland;	
Amanda Elliott	Broad Institute, Cambridge, MA, USA and	aelliott@broadinstitute.org
Amanda Elliott	-	asinor estradinorde.oly
	Massachusetts General Hospital, Boston, MA,	
	USA	
Kati Kristiansson	THL Biobank / Finnish Institute for Health and	kati.kristiansson@thl.fi
	Welfare (THL), Helsinki, Finland	

	Finnish Red Cross Blood Service / Finnish	
Mikko Arvas		milder an en Queria de statu
	Hematology Registry and Clinical Biobank,	mikko.arvas@veripalvelu.fi
	Helsinki, Finland	
Kati Hyvärinen	Finnish Red Cross Blood Service, Helsinki, Finland	kati.hyvarinen@veripalvelu.fi
Jarmo Ritari	Finnish Red Cross Blood Service, Helsinki, Finland	jarmo.ritari@veripalvelu.fi
Olli Carpén	Helsinki Biobank / Helsinki University and Hospital	alli aamaa @halaialii fi
	District of Helsinki and Uusimaa, Helsinki	olli.carpen@helsinki.fi
	Northern Finland Biobank Borealis / University of	
Johannes Kettunen	Oulu / Northern Ostrobothnia Hospital District,	johannes.kettunen@oulu.fi
	Oulu, Finland	
Katri Pylkäs	University of Oulu, Oulu, Finland	katri.pylkas@oulu.fi
Eeva Sliz	University of Oulu, Oulu, Finland	eeva.sliz@oulu.fi
Minna Karjalainen	University of Oulu, Oulu, Finland	minna.k.karjalainen@oulu.fi
	Northern Finland Biobank Borealis / University of	
Tuomo Mantere	Oulu / Northern Ostrobothnia Hospital District,	tuomo.mantere@oulu.fi
	Oulu, Finland	
	Finnish Clinical Biobank Tampere / University of	
Eeva Kangasniemi	Tampere / Pirkanmaa Hospital District, Tampere,	eeva.kangasniemi@pshp.fi
	Finland	
Sami Heikkinen	University of Eastern Finland, Kuopio, Finland	sami.heikkinen@uef.fi
	Biobank of Eastern Finland / University of Eastern	
Arto Mannermaa	Finland / Northern Savo Hospital District, Kuopio,	arto.mannermaa@uef.fi
	Finland	
Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland	eija.k.laakkonen@jyu.fi
Nice Diff. Texas	Auria Biobank / University of Turku / Hospital	
Nina Pitkänen	District of Southwest Finland, Turku, Finland	Niina.Pitkanen@tyks.fi
<u> </u>	Translational Sciences, Sanofi R&D, Framingham,	
Samuel Lessard	MA, USA	samuel.lessard@sanofi.com
	Translational Sciences, Sanofi R&D, Framingham,	
Clément Chatelain	MA, USA	clement.chatelain@sanofi.com
	Auria Biobank / University of Turku / Hospital	Lila.Kallio@tyks.fi
Lila Kallio	District of Southwest Finland, Turku, Finland	
T "	THL Biobank / Finnish Institute for Health and	
Tiina Wahlfors	Welfare (THL), Helsinki, Finland	tiina.wahlfors@thl.fi
Jukka Partanen	Finnish Red Cross Blood Service / Finnish	
	Hematology Registry and Clinical Biobank,	jukka.partanen@veripalvelu.fi
	Helsinki, Finland	
Eero Punkka	Helsinki Biobank / Helsinki University and Hospital	
	District of Helsinki and Uusimaa, Helsinki	eero.punkka@hus.fi

Daine Comi	Northern Finland Biobank Borealis / University of	ii@t
Raisa Serpi	Oulu / Northern Ostrobothnia Hospital District,	raisa.serpi@ppshp.fi
	Oulu, Finland	
Sanna Siltanen	Finnish Clinical Biobank Tampere / University of	
	Tampere / Pirkanmaa Hospital District, Tampere,	sanna.siltanen@pshp.fi
	Finland	
	Biobank of Eastern Finland / University of Eastern	
Veli-Matti Kosma	Finland / Northern Savo Hospital District, Kuopio,	veli-matti.kosma@uef.fi
	Finland	
	Central Finland Biobank / University of Jyväskylä /	
Teijo Kuopio	Central Finland Health Care District, Jyväskylä,	teijo.kuopio@ksshp.fi
	Finland	
	Institute for Molecular Medicine Finland (FIMM),	
Anu Jalanko	HiLIFE, University of Helsinki, Helsinki, Finland	anu.jalanko@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Huei-Yi Shen	HiLIFE, University of Helsinki, Helsinki, Finland	huei-yi.shen@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Risto Kajanne	HiLIFE, University of Helsinki, Helsinki, Finland	risto.kajanne@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	
Mervi Aavikko		mervi.aavikko@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Helen Cooper	Institute for Molecular Medicine Finland (FIMM),	helen.cooper@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Denise Öller	Institute for Molecular Medicine Finland (FIMM),	denise.oller@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
	Institute for Molecular Medicine Finland (FIMM),	
Rasko Leinonen	HiLIFE, University of Helsinki, Helsinki, Finland;	rasko@ebi.ac.uk
	European Molecular Biology Laboratory, European	
	Bioinformatics Institute, Cambridge, UK	
	Finnish Clinical Biobank Tampere / University of	henna.palin@pshp.fi
Henna Palin	Tampere / Pirkanmaa Hospital District, Tampere,	
	Finland	
	Helsinki Biobank / Helsinki University and Hospital	malla-maria.linna@hus.fi
Malla-Maria Linna	District of Helsinki and Uusimaa, Helsinki	
	Institute for Molecular Medicine Finland (FIMM),	
Mitja Kurki	HiLIFE, University of Helsinki, Helsinki, Finland;	mkurki@broadinstitute.org
	Broad Institute, Cambridge, MA, United States	
	Institute for Molecular Medicine Finland (FIMM),	
Juha Karjalainen	HiLIFE, University of Helsinki, Helsinki, Finland	juha.karjalainen@helsinki.fi
	, , ,,	

	HiLIFE, University of Helsinki, Helsinki, Finland	
Arto Lehisto	Institute for Molecular Medicine Finland (FIMM),	arto.lehisto@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Juha Mehtonen	Institute for Molecular Medicine Finland (FIMM),	juha.mehtonen@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	juna.mentonen@neisinki.ti
Wei Zhou	Broad Institute, Cambridge, MA, United States	wzhou@broadinstitute.org
Masahiro Kanai	Broad Institute, Cambridge, MA, United States	mkanai@broadinstitute.org
Mutaamba Maasha	Broad Institute, Cambridge, MA, United States	mmaasha@broadinstitute.org
Zhili Zheng	Broad Institute, Cambridge, MA, United States	zhengzhi@broadinstitute.org
Hannele Laivuori	Institute for Molecular Medicine Finland (FIMM),	hannele.laivuori@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	namele.laivuon@heismki.li
	Institute for Molecular Medicine Finland (FIMM),	
	HiLIFE, University of Helsinki, Helsinki, Finland;	alii haradiya a @halaialii fi
Aki Havulinna	Finnish Institute for Health and Welfare (THL),	aki.havulinna@helsinki.fi
	Helsinki, Finland	
	Institute for Molecular Medicine Finland (FIMM),	
Susanna Lemmelä	HiLIFE, University of Helsinki, Helsinki, Finland	susanna.lemmela@helsinki.fi
Turana Kiishisaa	Institute for Molecular Medicine Finland (FIMM),	
Tuomo Kiiskinen	HiLIFE, University of Helsinki, Helsinki, Finland	tuomo.kiiskinen@helsinki.fi
	Institute for Molecular Medicine Finland (FIMM),	laura.lahtela@helsinki.fi
L. Elisa Lahtela	HiLIFE, University of Helsinki, Helsinki, Finland	
Mari Kaunisto	Institute for Molecular Medicine Finland (FIMM),	mari.kaunisto@helsinki.fi
Man Raunsio	HiLIFE, University of Helsinki, Helsinki, Finland	man.kaunisto@neisinki.ii
Elina Kilpeläinen	Institute for Molecular Medicine Finland (FIMM),	alina kilaalainan@halainki fi
	HiLIFE, University of Helsinki, Helsinki, Finland	elina.kilpelainen@helsinki.fi
Timo P. Sipilä	Institute for Molecular Medicine Finland (FIMM),	time a sizile@helsisl <i>i</i> .fi
Timo F. Siplia	HiLIFE, University of Helsinki, Helsinki, Finland	timo.p.sipila@helsinki.fi
Oluwaseun Alexander Dada	Institute for Molecular Medicine Finland (FIMM),	alexander.dada@helsinki.fi
Oluwaseun Alexander Daua	HiLIFE, University of Helsinki, Helsinki, Finland	
Awaisa Ghazal	Institute for Molecular Medicine Finland (FIMM),	awaisa.ghazal@helsinki.fi
Awaisa Ghazai	HiLIFE, University of Helsinki, Helsinki, Finland	
Anastasia Kytölä	Institute for Molecular Medicine Finland (FIMM),	anastasia.shcherban@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	
Rigbe Weldatsadik	Institute for Molecular Medicine Finland (FIMM),	rigbe.weldatsadik@helsinki.fi
TABLE MEILIAISAUIN	HiLIFE, University of Helsinki, Helsinki, Finland	
Sanni Ruotsalainen	Institute for Molecular Medicine Finland (FIMM),	sanni.ruotsalainen@helsinki.fi
	HiLIFE, University of Helsinki, Helsinki, Finland	ระเทท.100เวลเลทธา ซายิเวทท.11
Kati Donnor	Institute for Molecular Medicine Finland (FIMM),	kati dannar@halainki fi
Kati Donner	HiLIFE, University of Helsinki, Helsinki, Finland	kati.donner@helsinki.fi

Timo P. Sipilä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	timo.p.sipila@helsinki.fi
Anu Loukola	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki	anu.loukola@hus.fi
Päivi Laiho	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	paivi.laiho@thl.fi
Tuuli Sistonen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	tuuli.sistonen@thl.fi
Essi Kaiharju	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	essi.kaiharju@thl.fi
Markku Laukkanen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	markku.laukkanen@thl.fi
Elina Järvensivu	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	elina.jarvensivu@thl.fi
Sini Lähteenmäki	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	sini.lahteenmaki@thl.fi
Lotta Männikkö	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	lotta.mannikko@thl.fi
Regis Wong	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	regis.wong@thl.fi
Auli Toivola	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	auli.toivola@thl.fi
Minna Brunfeldt	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	minna.brunfeldt@thl.fi
Hannele Mattsson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	hannele.mattsson@thl.fi
Kati Kristiansson	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	kati.kristiansson@thl.fi
Susanna Lemmelä	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	susanna.lemmela@helsinki.fi
Sami Koskelainen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	sami.koskelainen@thl.fi
Tero Hiekkalinna	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	tero.hiekkalinna@helsinki.fi
Teemu Paajanen	THL Biobank / Finnish Institute for Health and Welfare (THL), Helsinki, Finland	teemu.paajanen@thl.fi
Priit Palta	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	priit.palta@helsinki.fi
Shuang Luo	Institute for Molecular Medicine Finland (FIMM),	shuang.luo@helsinki.fi

	HiLIFE, University of Helsinki, Helsinki, Finland	
Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland	tarja.laitinen@pshp.fi
Mary Pat Reeve	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	mary.reeve@helsinki.fi
Shanmukha Sampath	Institute for Molecular Medicine Finland (FIMM),	aam nadmanabhuni@balainki fi
Padmanabhuni	HiLIFE, University of Helsinki, Helsinki, Finland	sam.padmanabhuni@helsinki.fi
Marianna Niemi	University of Tampere, Tampere, Finland	marianna.niemi@tuni.fi
Harri Siirtola	University of Tampere, Tampere, Finland	harri.siirtola@tuni.fi
Javier Gracia-Tabuenca	University of Tampere, Tampere, Finland	javier.graciatabuenca@tuni.fi
Mika Helminen	University of Tampere, Tampere, Finland	mika.helminen@tuni.fi
Tiina Luukkaala	University of Tampere, Tampere, Finland	tiina.luukkaala@tuni.fi
lida Vähätalo	University of Tampere, Tampere, Finland	iida.vahatalo@epshp.fi
Jyrki Tammerluoto	Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland	jyrki.tammerluoto@helsinki.fi
Marco Hautalahti	Finnish Biobank Cooperative - FINBB	marco.hautalahti@finbb.fi
Johanna Mäkelä	Finnish Biobank Cooperative - FINBB	johanna.makela@finbb.fi
Sarah Smith	Finnish Biobank Cooperative - FINBB	sarah.smith@finbb.fi
Tom Southerington	Finnish Biobank Cooperative - FINBB	tom.southerington@finbb.fi
Petri Lehto	Finnish Biobank Cooperative - FINBB	petri.lehto@finbb.fi